Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Voyager Therapeutics, Inc is a biotechnology business based in the US. Voyager Therapeutics shares (VYGR) are listed on the NASDAQ and all prices are listed in US Dollars. Voyager Therapeutics employs 185 staff and has a trailing 12-month revenue of around USD$197.3 million.
|52-week range||USD$6.26 - USD$14.62|
|50-day moving average||USD$7.8576|
|200-day moving average||USD$9.6496|
|Wall St. target price||USD$11.55|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$1.068|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Voyager Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Voyager Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Voyager Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, Voyager Therapeutics shares trade at around 6x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Voyager Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$40.9 million.
The EBITDA is a measure of a Voyager Therapeutics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$197.3 million|
|Operating margin TTM||18.93%|
|Gross profit TTM||USD$-15,344,000|
|Return on assets TTM||7.23%|
|Return on equity TTM||29.22%|
|Market capitalisation||USD$242.4 million|
TTM: trailing 12 months
There are currently 1.9 million Voyager Therapeutics shares held short by investors – that's known as Voyager Therapeutics's "short interest". This figure is 20.6% up from 1.6 million last month.
There are a few different ways that this level of interest in shorting Voyager Therapeutics shares can be evaluated.
Voyager Therapeutics's "short interest ratio" (SIR) is the quantity of Voyager Therapeutics shares currently shorted divided by the average quantity of Voyager Therapeutics shares traded daily (recently around 416429.69432314). Voyager Therapeutics's SIR currently stands at 4.58. In other words for every 100,000 Voyager Therapeutics shares traded daily on the market, roughly 4580 shares are currently held short.
However Voyager Therapeutics's short interest can also be evaluated against the total number of Voyager Therapeutics shares, or, against the total number of tradable Voyager Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Voyager Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Voyager Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0737% of the tradable shares (for every 100,000 tradable Voyager Therapeutics shares, roughly 74 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Voyager Therapeutics.
Find out more about how you can short Voyager Therapeutics stock.
We're not expecting Voyager Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Voyager Therapeutics's shares have ranged in value from as little as $6.26 up to $14.62. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Voyager Therapeutics's is 1.0923. This would suggest that Voyager Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and alpha-synuclein program for synucleinopathies, Parkinson's disease, Lewy Body Dementia, and multiple system atrophy. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.